Scancell Holdings Plc (LON:SCLP) hailed latest findings from the Phase 1/2 clinical trial of lead cancer drug SCIB1, which continues to show what it called "compelling" survival data.
The firm's first immunoBody candidate, named SCIB1, is being developed to treat melanoma - the most dangerous form of skin cancer.
Chief executive Dr Richard Goodfellow told investors on Wednesday that the drug continues to deliver compelling survival data in patients with resected Stage III/IV melanoma, where the diseased tissue has been cut away in surgery.
"It is particularly interesting to note that there has only been one new case of disease progression since November 2013 in the resected patients receiving 4mg doses of SCIB1, which gives us hope that SCIB1 might offer curative potential in this currently untreated patient group," he added.
As at June 27, there were 19 of 20 patients with resected tumours when they entered the study that remain alive, the firm said, and of 16 patients who received 2-4mg doses of SCIB1, only one case of the disease progressing has been noted.
As reported on June 17, treatment for eight patients in the long-term continued dosing phase has been suspended due to the clinical trial supplies no longer being within the original specification
New SCIB1 material will be ready for use in around nine-12 months, the group added.
Meanwhile, plans for the US clinical study of SCIB1 in combination with a checkpoint inhibitor remain on track, while the final clinical study report will be issued later this year and give safety, immunology and clinical data from all patients up to October 29 last year - the date of the last patient's dose in the main study to support Scancell's US regulatory submission.
Shares gained over 13% to stand at 17p each.